Q-omics provides the consensus-scored MEIS2 profile across patient tissues and cancer cell-line models. MEIS2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MEIS2 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, MEIS2 RNA expression shows 17,751 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where MEIS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MEIS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MEIS2 survival associations across molecular data types. MEIS2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MEIS2 RNA expression–survival associations across cancer types. High MEIS2 expression shows unfavorable associations in KIRP, UVM, THCA and BLCA, but favorable associations in KIRC and MESO. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MEIS2 RNA expression.
This table summarizes MEIS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MEIS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MEIS2 shows lower tumor expression in KIRC, KIRP, COAD, KICH, UCEC and BRCA. The KIRC box plot shows higher MEIS2 RNA expression in normal versus tumor tissue (log2 FC = −0.914, t-test p < 0.001).
This table shows molecular features associated with MEIS2 in patient tissues and cancer cell lines. In patient samples, MEIS2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MEIS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
